Search Within

Genitourinary Oncology Service

  1. "EJC Supplements"
Formats
  1. Meeting Abstract (19)
Groups
  1. Department of Medicine (19)
  2. Solid Tumor Oncology Division (19)
  3. GSK Faculty (7)
  4. Human Oncology and Pathogenesis Program (7)
  5. Molecular Pharmacology and Chemistry Program Faculty (6)
  6. Sloan Kettering Institute Faculty (6)

More Groups

People
  1. Robert Motzer (9)
  2. David Solit (6)
  3. Neal Rosen (5)
  4. Howard Scher (3)
  5. Qing Ye (3)
  6. Gnanamba Kondagunta (2)

More People

Years
  1. 2008 (2)
  2. 2007 (9)
  3. 2006 (5)
  4. 2005 (3)
Publications
  1. EJC Supplements (19)
Publishers
  1. Pergamon-Elsevier Science Ltd (19)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Potent anticancer activity of panobinostat (LBH589) in models of hormone-refractory prostate cancer (HRPC): Targeting the androgen receptor
    Meeting Abstract

    Shao, W.; Growney, J.; O'Connor, G.; Feng, Y.; Scher, H.; Yao, Y. M.; Fawell, S.; Atadja, P.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium
    Meeting Abstract

    Scher, H.; Beer, T.; Higano, C.; Logothetis, C.; Shelkey, J.; Hung, D.; Hirmand, M.; Larson, S.; Fleisher, M.; Sawyers, C.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Targeting MEK in tumors with BRAF and RAS mutations
    Meeting Abstract

    Solit, D.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Redman, B. G.; Hudes, G. R.; Kondagunta, G. V.; Patel, P. H.; Kim, S. T.; Chen, I.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Economic evaluation of sunitinib vs. interferon-alfa (IFN-alpha) in first-line metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Negrier, S.; Remak, E.; Brown, R.; Kim, S. T.; Charbonneau, C.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated efficacy and safety results and further analysis of prognostic factors
    Meeting Abstract

    Motzer, R. J.; Michaelson, M. D.; Hutson, T. E.; Tomczak, P.; Bukowski, R. M.; Rixe, O.; Negrier, S.; Kim, S. T.; Chen, I.; Figlin, R. A.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): Results of a dose-finding study
    Meeting Abstract

    Kondagunta, G. V.; Hudes, G.; Figlin, R.; Wilding, G.; Hariharan, S.; Kempin, S.; Fayyad, R.; Hoosen, S.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Houk, B. E.; Bello, C. L.; Michaelson, M. D.; Bukowski, R. M.; Redman, B.; Hudes, G. R.; Wilding, G.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    George, D. J.; Michaelson, M. D.; Rosenberg, J. E.; Redman, B. G.; Hudes, G. R.; Bukowski, R. M.; Kim, S. T.; Chen, I.; Wilding, G.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)
    Meeting Abstract

    Gallagher, D. J.; Milowsky, M. I.; Gerst, S. R.; Iasonos, A.; Boyle, M.; Riches, J.; Bajorin, D. B.
    EJC Supplements (2007)

    Fulltext@MSK | Save